6 ms·
FDA doesn’t approve based on the projected costs to the system. That’s the underlying problem. There is no political mechanism to say “no, this treatment won’t
by elhudy 5y ago
FDA doesn’t approve based on the projected costs to the system. That’s the underlying problem. There is no political mechanism to say “no, this treatment won’t be covered by medicare.” Further, such a mechanism would be wildly unpopular with your average voter. Nobody wants to deny their grandmas coverage to anything, and it’s a huge burden on the system and contributor to inflation.
- lotsofpulp 5y agoIt would not be under the FDA’s purview (nor should it be) to do a cost benefit analysis anyway. Their job is to vet medical claims, regardless of price. Whether or not taxpayers should pay for a certain treatment for a certain population is a political excercise, usually implemented via CMS, but also state Medicaid departments.
- elhudy 5y agoTrue, with one caveat, state medicaid departments have like no incentive to not cover procedures or medications because they are 90%+ funded through the fed anyway. But most alz patients probably fall under medicare anyway.